Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperbaric bupivacaine + isobaric bupivacaine is a combination of two forms of bupivacaine used for spinal anesthesia. Bupivacaine is an amide-type local anesthetic available in two distinct formulations that differ in baricity: hyperbaric bupivacaine (containing dextrose, making it denser than cerebrospinal fluid) and isobaric bupivacaine (dextrose-free, with density similar to cerebrospinal fluid)[1][2]. When administered together, either sequentially or as a mixture, these formulations provide unique benefits compared to using either form alone. The combination appears to offer advantages including: - Greater hemodynamic stability with less hypotension - Extended duration of both sensory and motor blockade - Balanced diffusion characteristics that combine the rapid onset of hyperbaric bupivacaine with the prolonged effect of isobaric bupivacaine[2][5][6] This combination has been studied particularly for cesarean sections and lower abdominal surgeries, where maintaining stable hemodynamics while providing adequate anesthesia is crucial[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperbaric bupivacaine + isobaric bupivacaine.